text: President Bush signed a Drug Safety bill giving the FDA more money and new powers to police potentially serious side effects of marketed prescription drugs. These amendments were introduced largely as a response to a string of recent high profile drug safety controversies. The bill gives the FDA the authority to require new warnings on drugs, order post-approval safety studies or limit distribution due to side effect considerations. Drug and device makers will also be required to post basic results for clinical trials on a public database. The legislation, which has received the support of the pharmaceutical industry, also increases fees paid by pharmaceutical companies to fund these initiatives.
  For more information, please see:
explanation: The text extract describes a Drug Safety bill signed by President Bush that grants the FDA additional funds and powers to monitor and address potential side effects of prescription drugs. It outlines the bill's provisions, including the authority to add warnings, conduct post-approval studies, and limit drug distribution. The extract also mentions the support of the pharmaceutical industry and the requirement for companies to post clinical trial results publicly.
distilabel_metadata.content: Evaluate the user given text extract and determine if it contains a math question and optionally and answer to this question.
  
  Output rules:
  
  1. Briefly describe the document and mention if it contains a question or a question and answer.
  2. Finalize the output with: Label: no-question,question,question-and-answer,multiple-question,multiple-question-and-answer
distilabel_metadata.role: system
distilabel_metadata.content: President Bush signed a Drug Safety bill giving the FDA more money and new powers to police potentially serious side effects of marketed prescription drugs. These amendments were introduced largely as a response to a string of recent high profile drug safety controversies. The bill gives the FDA the authority to require new warnings on drugs, order post-approval safety studies or limit distribution due to side effect considerations. Drug and device makers will also be required to post basic results for clinical trials on a public database. The legislation, which has received the support of the pharmaceutical industry, also increases fees paid by pharmaceutical companies to fund these initiatives.
  For more information, please see:
distilabel_metadata.role: user
distilabel_metadata.raw_output_q_a_detector_0: The text extract describes a Drug Safety bill signed by President Bush that grants the FDA additional funds and powers to monitor and address potential side effects of prescription drugs. It outlines the bill's provisions, including the authority to add warnings, conduct post-approval studies, and limit drug distribution. The extract also mentions the support of the pharmaceutical industry and the requirement for companies to post clinical trial results publicly. 
  
  Label: no-question